0000950170-21-003731.txt : 20211109 0000950170-21-003731.hdr.sgml : 20211109 20211109160543 ACCESSION NUMBER: 0000950170-21-003731 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20211109 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20211109 DATE AS OF CHANGE: 20211109 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Singular Genomics Systems, Inc. CENTRAL INDEX KEY: 0001850906 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 812948451 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40443 FILM NUMBER: 211392064 BUSINESS ADDRESS: STREET 1: 10931 N. TORREY PINES ROAD, SUITE #100 CITY: LA JOLLA STATE: CA ZIP: 92037 BUSINESS PHONE: (858) 333-7830 MAIL ADDRESS: STREET 1: 10931 N. TORREY PINES ROAD, SUITE #100 CITY: LA JOLLA STATE: CA ZIP: 92037 8-K 1 omic-20211109.htm 8-K 8-K
0001850906false00018509062021-11-092021-11-09

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 9, 2021

 

 

Singular Genomics Systems, Inc.

(Exact name of registrant as specified in its charter)

 

 

Delaware

001-40443

81-2948451

(State or other jurisdiction
of incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

10931 N. Torrey Pines Road, Suite #100
La Jolla, California 92037

 

(858) 333-7830
(Registrant’s address of principal executive offices

and telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of Each Class

 

Trading
Symbol(s)

 


Name of Each Exchange on Which Registered

Common Stock, par value $0.0001 per share

 

OMIC

 

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

Item 2.02 Results of Operations and Financial Condition.

On November 9, 2021, Singular Genomics Systems, Inc. (the “Company”) issued a press release regarding the Company’s financial results for the quarter ended September 30, 2021. A copy of the press release is attached as Exhibit 99.1 and incorporated herein by reference.



The information in this Item 2.02 and the press release attached as Exhibit 99.1 hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

 

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

99.1

Press Release dated November 9, 2021

104

Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Singular Genomics Systems, Inc.

 

 

 

 

Dated:

November 9, 2021

By:

/s/ Dalen Meeter

 

 

 

Dalen Meeter
Senior Vice President, Finance
Principal Financial Officer and Principal Accounting Officer

 

 

 EX-99.1 2 omic-ex99_1.htm EX-99.1 EX-99.1

img160378605_0.jpg 

 

Singular Genomics Systems, Inc. Reports Recent Highlights and Third Quarter Financial Results

 

La Jolla, CA, November 9, 2021 – Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company focused on delivering genomic technologies for the advancement of science and medicine, today highlighted recent corporate achievements and reported financial results for the third quarter of 2021.

 

“Early access partnerships for the G4 have been successful, and our partners are achieving accuracy and performance measures at our intended targeted specs. We are grateful for the collaboration of our partners at these pioneering labs as we establish robust installation protocols, further enhance system performance and lock in manufacturing operations,” said Drew Spaventa, Chairman and Chief Executive Officer. “We remain on track for our commercial launch, to take orders by year end and to ship commercial systems during the first half of 2022. The commercial team is ramping to drive instrument placements and deliver an unparalleled customer experience.”

 

Recent Highlights

Achieved targeted performance specifications at three Early Access Program (EAP) partners’ labs with the G4 Integrated Solution. Results from next generation sequencing (NGS) runs performed by partners demonstrated the following:
o
Harvard’s Beth Israel Deaconess Medical Center achieved average read counts of 136 million per flow cell and accuracy of 99.6%–99.7% utilizing targeted sequencing panels requiring 100 cycle kits.
o
Site 2 achieved average read counts of greater than 150 million per flow cell and accuracy of 99.6%–99.8% utilizing targeted sequencing panels requiring 150 cycle kits.
o
Site 3 achieved average read counts of greater than 170 million per flow cell and accuracy of approximately 99.8% utilizing targeted panels and exome libraries requiring 200 cycle kits.

 

Added an additional three EAP partners, for a total of six, to further validate the G4 performance specifications across various applications and lab settings that represent our targeted early customers and markets.

 

G4 commercial launch remains on track for the end of 2021. As part of commercial launch, we plan to include the release of specifications and pricing for the G4 instrument and initial consumable kit configurations, publish a technical report and provide known data sets for evaluation by prospective customers. Preparations are underway to accept limited orders from thought leading organizations by year end with initial shipments targeted during the first half of 2022.

 

Advanced operational readiness through continued hiring of manufacturing, customer support, sales and other commercial personnel and completed the buildout of a dedicated manufacturing facility to support the launch and anticipated initial demand for both the G4 and PX Integrated Solutions.

 

 

Financial Results

Operating expenses for the third quarter of 2021 totaled $17.5 million, compared to $7.8 million for the third quarter of 2020. Operating expenses for the third quarter of 2021 included non-cash stock-based compensation of $2.9 million. The year-over-year increase in operating expenses was driven primarily by headcount growth, investments to support the G4 commercial launch and continued investment in the PX Integrated Solution development.

 

Net loss for the third quarter of 2021 was $17.6 million, or $0.25 per common share, compared to $7.9 million, or $0.74 per common share, for the third quarter of 2020.

 

Cash, cash equivalents and short-term investments, excluding restricted cash, at September 30, 2021 totaled approximately $357.0 million.

 

Webcast and Conference Call Details

Singular Genomics’ management team will host a conference call today, November 9, 2021, beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.singulargenomics.com, on the Investors page in the Presentations & Events section.

 

About Singular Genomics Systems, Inc.

Singular Genomics is a life science technology company that is leveraging novel, next generation sequencing (NGS) and multiomics technologies to build products that empower researchers and clinicians. Our mission is to accelerate genomics for the advancement of science and medicine. Our Singular Sequencing Engine is the foundational platform technology that forms the basis of our products in development as well as our core product tenets: accuracy, speed, flexibility and scale. We are currently developing two integrated solutions that are purpose built to target applications in which these core product tenets matter most. Our first integrated solution, the G4 Integrated Solution, is targeted at the NGS market. Our second integrated solution in development, the PX Integrated Solution, combines single cell analysis, spatial analysis, genomics and proteomics in one integrated instrument to offer a versatile multiomics solution. The G4 and PX Integrated Solutions are both comprised of an instrument and an associated menu of consumable kits.

 

 

Forward-Looking Statements

Certain statements contained in this press release, other than historical information, constitute forward-looking statements within the meaning of the Federal securities laws. Forward-looking statements include, but are not limited to, statements regarding: (i) our ability to successfully complete the development of our G4 and PX Integrated Solutions; (ii) our ability to meet our commercial launch and product delivery timelines and objectives; and (iii) our ability to achieve customer and scientific acceptance for our G4 and PX Integrated Solutions. Any such forward-looking statements are based on our management’s current expectations and are subject to a number of risks and uncertainties that could cause our actual future results to differ materially from our management’s current expectations or those implied by the forward-looking statements. These risks and uncertainties include, but are not limited to: (i) we have incurred significant losses since inception, we expect to incur significant losses in the future and we may not be able to generate sufficient revenue to achieve and maintain profitability; (ii) we have no history commercializing our products or technology; (iii) the life sciences technology market is highly competitive, and if we fail to compete effectively, our business and operating results will suffer; (iv) if we are sued for infringing, misappropriating or otherwise violating intellectual property rights of third parties, this litigation could be costly and time consuming and could prevent or delay us from developing or commercializing our product candidates; (v) if our products fail to achieve early customer and scientific acceptance, we may not be able to achieve broader market acceptance for our products, and our revenues and prospects may be harmed; and (vi) the COVID-19 pandemic and efforts to reduce its spread have adversely impacted, and may materially and adversely impact, our business and operations. These and other risk factors that may affect our future results of operations are identified and described in more detail in our filings with the SEC, including our Quarterly Report on Form 10-Q for period ended September 30, 2021, filed with the SEC on November 9, 2021. Accordingly, you should not rely upon forward-looking statements as predictions of future events or our future performance. Except as required by applicable law, we undertake no obligation to update publicly or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

 

Investor Contact

Matt Clawson

949-370-8500

ir@singulargenomics.com

 

Media Contact

Dan Budwick, 1AB

973-271-6085

dan@1abmedia.com

 

 

 

Singular Genomics Systems, Inc.

Statements of Operations

(In thousands, except share and per share data)

(Unaudited)

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

Research and development

$

8,910

 

 

$

6,080

 

 

$

23,200

 

 

$

15,431

 

Selling, general and administrative

 

8,551

 

 

 

1,698

 

 

 

18,406

 

 

 

4,518

 

Total operating expenses

 

17,461

 

 

 

7,778

 

 

 

41,606

 

 

 

19,949

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss from operations

 

(17,461

)

 

 

(7,778

)

 

 

(41,606

)

 

 

(19,949

)

 

 

 

 

 

 

 

 

 

 

 

 

Other income (expense):

 

 

 

 

 

 

 

 

 

 

 

Interest income

 

91

 

 

 

76

 

 

 

223

 

 

 

444

 

Interest expense

 

(234

)

 

 

(202

)

 

 

(654

)

 

 

(503

)

Change in fair value of convertible promissory notes

 

-

 

 

 

-

 

 

 

(35,199

)

 

 

-

 

Change in fair value of warrant liability

 

-

 

 

 

(49

)

 

 

(2,180

)

 

 

(49

)

Other (expense) income

 

(7

)

 

 

20

 

 

 

405

 

 

 

24

 

Net loss

$

(17,611

)

 

$

(7,933

)

 

$

(79,011

)

 

$

(20,033

)

 

 

 

 

 

 

 

 

 

 

 

 

Net loss per share:

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted net loss per share

$

(0.25

)

 

$

(0.74

)

 

$

(2.05

)

 

$

(1.91

)

Weighted-average shares used to compute basic and diluted net loss per share

 

71,721,861

 

 

 

10,726,496

 

 

 

38,553,685

 

 

 

10,507,732

 

 

 

Singular Genomics Systems, Inc.

Condensed Balance Sheets

(In thousands, except share and par value amounts)

 

 

 

 September 30,

 

 

 December 31,

 

 

 

2021

 

 

2020

 

 

 

(Unaudited)

 

 

 

 

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

239,263

 

 

$

11,688

 

Short-term investments

 

 

117,750

 

 

 

15,231

 

Prepaid expenses and other current assets

 

 

7,214

 

 

 

652

 

Total current assets

 

 

364,227

 

 

 

27,571

 

Property and equipment, net

 

 

4,917

 

 

 

2,368

 

Restricted cash

 

 

687

 

 

 

482

 

Other noncurrent assets

 

 

1,000

 

 

 

81

 

Total assets

 

$

370,831

 

 

$

30,502

 

 

 

 

 

 

 

 

Liabilities, Convertible Preferred Stock and Stockholders’ Equity (Deficit)

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

2,390

 

 

$

427

 

Accrued expenses

 

 

3,443

 

 

 

1,592

 

Current portion of long-term debt, net of issuance costs

 

 

-

 

 

 

926

 

Warrant liability

 

 

-

 

 

 

451

 

Other current liabilities

 

 

158

 

 

 

294

 

Total current liabilities

 

 

5,991

 

 

 

3,690

 

Long-term debt, net of issuance costs

 

 

9,868

 

 

 

8,469

 

Other noncurrent liabilities

 

 

2,904

 

 

 

714

 

Total liabilities

 

 

18,763

 

 

 

12,873

 

Commitments and contingencies

 

 

 

 

 

 

Convertible preferred stock, $0.0001 par value:

 

 

 

 

 

 

Series Seed, 6,520,790 shares authorized, 0 and 6,520,790 issued and outstanding at September 30, 2021 and December 31, 2020, respectively; liquidation preference of $0 and $4,499,998 at September 30, 2021 and December 31, 2020, respectively

 

 

-

 

 

 

4,486

 

Series A, 12,932,429 shares authorized, 0 and 12,932,429 issued and outstanding at September 30, 2021 and December 31, 2020, respectively; liquidation preference of $0 and $20,000,002 at September 30, 2021 and December 31, 2020, respectively

 

 

-

 

 

 

19,908

 

Series B, 19,566,903 shares authorized, 0 and 19,373,169 issued and outstanding at September 30, 2021 and December 31, 2020, respectively; liquidation preference of $0 and $44,999,997 at September 30, 2021 and December 31, 2020, respectively

 

 

-

 

 

 

44,790

 

Stockholders’ equity (deficit):

 

 

 

 

 

 

Common stock, $0.0001 par value; 400,000,000 and 60,272,685 shares authorized, 71,934,170 and 10,816,937 of shares outstanding at September 30, 2021 and December 31, 2020, respectively

 

 

7

 

 

 

1

 

Additional paid-in capital

 

 

484,202

 

 

 

1,552

 

Accumulated other comprehensive (loss) gain

 

 

(5

)

 

 

17

 

Accumulated deficit

 

 

(132,136

)

 

 

(53,125

)

Total stockholders’ equity (deficit)

 

 

352,068

 

 

 

(51,555

)

Total liabilities, convertible preferred stock and stockholders’ equity

 

$

370,831

 

 

$

30,502

 

 

 GRAPHIC 3 img160378605_0.jpg GRAPHIC begin 644 img160378605_0.jpg M_]C_X 02D9)1@ ! @ 0 ! #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W^BBB@ HH MHH **** "BBB@ HHJ"[O+:PMVN+N>."%>KR, !0!/1TKSO6OBK90%HM(MS=. M./.ERL?X#J?TKG$D\8^,FR/M#6[>G[J$?X_K0!Z=J'BK1-,)6XOXC(/^6<9W MM^0KG;OXEVP)%E822>CS,%'Y#-5-,^%X4!M2ON>\=NN/_'C_ (5U=CX1T.P M,5A&[#^.7YS^M '&GQKX@OVQ:PHF>T,)<_KFI4'C&\Y)O5!]Q&/Z5Z,D:1+M MC147T48%.H \^7P]XDFYED?_ ('/[KK M^$IJ9=.UZ#HTO_ 9L_UKKZ* .66ZUJW_ -8)L?[29JS#KUP#B6)&^F0:Z"F2 M0Q2C$D:M]10!2AU>WD^^&C/N,BKJ2QRC*.K#V-5)-*MFY0&,_P"R:@.FS0G, M;AOIP: -6BL^.YFC.V0$_P"]UJY',DGL?0T 24444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !2$A5+,0 !DD]JS]:US3O M#^G/?:E*:[XTU_P ?:B-*TBWFBM'.%MHC\T@]9&[#VZ?6 M@#N?%'Q4L-,+VFCA+ZZ'#2Y_=(?K_$?I^=<;9:)XK\?W2WEW*_V8GB>?Y8U' M^PO?\/SKL/"7PKLM+6.[UK9>7@P1"/\ 51GZ?Q'Z\>U>B*H50J@ 8 ':@#D M]!^'FBZ,%DEC^VW(Y\R<9 /LO0?K76 !0 !T I:BN+F"TA::XF2*)>KNP4 M#\30!+17%ZG\2]'M"T=DLE](.Z?*G_?1_H*YN3QQXDUF0Q:?#Y0/&VVB+M^9 MH ]79@HRQ 'J:I3ZUIEOQ+?VZGT\P$UYU%X6\4ZJ0]Z[J#WN9\_H,UK6OP[= M<&XU!1[11Y_4F@#I'\5Z*O2]#?[J,?Z4P>+=))XED/\ VS-4HO E@GW[FX?\ M0/Z5:7P=I:]YS]9/_K4 6$\3:6__ "V]0FV Y0_@:GH MH KJ[QG!_6IE<,.*4@,,$5&8RIR.E $M%,5\]:?0 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !7.^+_&.G>#]-^T7;>9<29$%LI^:0_P!! MZFF>-/&5CX-T'];^*7B6;4]2G=;0/^_N,< M*.T<8_SCJ: );*S\2_%?Q"UQ/)LMHSAI"#Y-LO\ =4=V_4]Z]Q\-^%M,\+6 MMM/APY'[V=N7D/J3_3I5[2]*LM%TZ*PT^!8+:(85%_F?4^]7* "HYIHK:%YI MY$CB099W. ![FL/Q3XQTOPG:"2]DWW#C]U;1GYW_ ,![FO'Y]1\4_$W5#;PH M1;*<^2A*PPCU<]S_ ) H [7Q%\6;6W+VVA1"YD'!N9.(Q]!U;]!7.6>@^+/& M\ZW5[)((#R);G*H!_LI_@/QKN?#'PVTK0E2>[ O[X<[Y%^1#_LK_ %-=KTH MXS2/AMH^GA7O"]],.OF?*G_?(_K7706T%K$(K>&.*,=%10H_2I:* "BBH)[V MUMA^_N88O]]P* )Z*R7\3:-&<'4(B?\ 9R?Y4P>*M()XN2?^ -_A0!LT5EIX MBTM^ESCZH?\ "K46I64WW+J(_P# L4 6J*0,&&5((]0:6@".2"*7[Z GU[U7 M:Q"\QM^!JY10!51Y(^&S]#5A9%;V/I2D C!&:B:+'*_E0!-14:.>C5)0 TKW M%5M0U*STBPEOM0N$M[:(9>1SP*MUR7Q!\'-XQT(6\-R\-U;L9(06/ENV.C#^ M1[4 =3!/#=6\<\$BRPR*&1T.0P/0@U)7SSX'\25=/$FR2-^6 MM6_O#U4]2/Q%?0<,T=Q"DT,BR12*&1U.0P/0@T /HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ K*\1^(+'PQH=QJNH/MAB'"C[TC'HJ^YK3=UCC:1V"HH) M9B< =Z^:?&?B/4/BCXXM](T8,]E'(8K1.S'^*9O;'Y#ZT )I=CK?Q>\;2W5 MT[16R$&9QRMM%GA%_P!H_P")-?1NE:59Z+ID&GZ? L-M"NU%'\SZD^M9_A/P MQ9>$M @TRS7)4;II2/FE<]6/^>!6Y0 5P?C_ .(]KX4B-C9;+C5Y%XCSE80? MXG_H.]1_$KXB1>$K/[!8,DFL7"Y13R(%_OM_0=_I7!_#GX>7'BBY_P"$A\0^ M8]D[F15D)W7;9Y8G^[G\_I0!'X2\$:OX\U!M:UJXF6RD;<\[_?G]D]%]^GI7 MNFF:79:-8QV6GVZ06Z#A5'7W)[GWJU'&D4:QQHJ(@"JJC '8"G4 %%17-S! M9V\EQ5>)OBTTDC6?AQ."=OVN1EZIK6G: M-!YVH7<4"GH&/S-]!U-<+J?Q40DQZ39%NPFN#@?@H_QK T7X?Z]XBG_M#69Y M;9).2\^6F<>P/3\?RKTG1_!NB:*JF"T668?\MI_G;_ ?A0!P<=QXS\2 M#-.0?ZVX/_ A_A71T4 8'_")V0^Y-./Q!_I2'PP%_P!7)]"N-*NI)(XY<$/&V"K#H?<9[&@"QH^LZ?KVG1W^F7*7%L^0&7L1U!'4' MV-7Z^;++4->^$?B][>Y0R6KD&6(']WU>?_ J\?S:! MJ(\+:ZS1VK2&.!I>#;29QL.>BD_D?K7OM>-_&?P +NVD\4:7#_I$2_Z;$@_U MB#_EH!ZCO[?2@#V2BO+O@[X^/B+2CHFHS;M3LD&QV/,\70'W(Z'\#7J- !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4451UG5;70M&O-4O'VV]K$TKGU [#W/3\: /+ M?CEXW_LO3$\-6,NVZO4W73*>8X?3ZM_('UJ]\&/ XT#0AK=]%C4;] 45AS## MU ]B>I_"O,/ VDW7Q0^)D^JZJI>U23[5= ],9_=Q#VX ^@-?4( P!T% ! M7+^._&5KX+\/O>R!9+N7,=K 3_K']_8=3_\ 7KHKJZ@L;2:ZN9%B@A0R2.QX M50,DU\R7=SJ7QA^)"Q6Y>.TR5BSTM[<'EC_M'^9 H T_A[X/O?B#X@GU_77> M6Q67?.[IJ[0 5D^(O$>G>&-+>_U*;8@X1!R\C?W5'K']?I0!&=+2PTZ$)&.7<\M(W]YCW-:M !1110 4444 %%%% !1110 4 M444 %&,]:** (S'@Y7\J7>%4LQ &23VI]3.W+Q]// M7NF[MG_ZU '4*P90RD%2,@@\$4M>$?#;XC3:#>KX;\0LZ6H?RH99N&MGSC8V M?X<_E]*]W!!&1R* .=\9>$++QCHCV-R DZY:WN .8G]?H>XKP[P9XHU'X9>+ M[C1M:5DL'EV74?41GM*OMC&?4?2OI.O-OB[X$'B;1#JEA$#JMBA("CF:/J4^ MHZC\N] 'H\V?2O:J /F/QUH5[\+_ !_;:OH^4M))#/:'^$?WXC[< M_D?:OH?PYKUIXF\/V>KV39AN$#;<\HW1E/N#D5G>/?"D7C'PG=::0HN0/-M9 M#_!*.GX'H?8UX[\#O%4NC>([GPIJ),<=V[&)'X\NX7AE_$#\U]Z /HBBBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHK%\7:Z/#/A+5-9VAFM8&=%/0OT M4?F10!S?C[XL:)X%/V1PU]JC+D6D3 ;!V+M_#].OM7B^H?M">,;J8M9QZ?91 M=D6'>1]2Q_I7FI;4/$6N N[W.H7\X&6.2\CG_$U]->&/@-X6TO3H_P"V86U2 M_*CS7>1EC4]PJJ1Q[F@#S?1_VB?$]I.O]J6=C?P9^8(IB?'L1D?I7O'@OQUH MWCG3#=Z7*RRQX$]M+@21$^H[CT(XKR7XJ?!?2M*\/7&O>&HY+-].OXI"(7E$-RN>'B8@-GZ=?J* /M6BBB@ HHH MH **** "BBB@!KMM1F] 37SC+^TAKD'].U&5%CDNK:.9D7HI902!^=:%8?@S_D1]!_[! M\'_H K(;;3;/3;2YCFMA,7F9 M@02S#''TI/AG\9QXSUN32-5M+>QNG7=:F)B5EQ]Y>>^.1^->??M&_P#(\Z=_ MV#U_]#>O([2[N+"\AN[69HKB%Q)'(IP58'((H ^^**X_X;^.(/'7A:*^RJ7\ M.(KR$?POZCV/4?B.U=A0!%RJ/YGJ:]!\$? 35-=MHM0\07#Z9: M2#PN;AN[RW3Y/_?) _2L77OV=_#MY S:+>76G MW&/E$C>;&3[@\C\Z -_P;\9O#/BR6.TDD;3-0?A8+DC:Y]%?H?H<&O1:^'_% M?@_6?!>K&PU>W\MC\T4R',%?$-P9=_R6-W(M6\,NZ?I[Z+IZ)=7,<+,KO MD!F )'/O7T)7PSX2_P"1RT/_ *_X/_1BU]S4 %>;_%?XD7WP^32VLK&VNOMA MD#>KTBO OVE_]5X<_WI__ &2@#I?A9\6-1\?:]>:?>:;:VL<% MMYP:%F))W 8Y^M>L5\S_ +-__(YZI_UX'_T8M?3% !1110 4444 %%%% !11 M10 5P/Q4\?7G@#2+"\L[."Z:YG,3+,2 %)R,5WU>)_M)_\ (KZ-_P!?K?\ MH!H L?#;XR:IXW\7)HUWI=G;Q- \OF1,Q;*XXY/O7LE?*/P _P"2GQ?]>-/$YT;4K" MVM&DA9[=H68[F7DJ<^V3^%> >)]8NO&GC:\U!$9YKZYVP1=]N=J*/PP*J:7? MWOA;Q-;7J*T=YI]R&9#U#*<,I_44 ?=5%5-+U&WU?2K34;5@UO=1++&?9AFK M= !1110 4444 %%%% !1110 5Y!\3OB_J?@3Q1'I-IIEI@#2_P"&D]<_Z 6G?]]O_C2K^TGK8/S:#IY' MM(XK%^$OPQTKQ_8ZG/J-Y>0-:2HB"W*@$,"3G(/I7HK?LW^&BI"ZOJH/8DQG M_P!EH S-,_:4MGD5=5\/2Q*3R]M.'Q_P%@/YUZ]X9\6Z+XOT[[;HUZLZ#B1# M\KQGT93R*^>O'7P(U'PUIDVJZ/>G4K2!=\T31[944=6&.& []#7 ^#/%E]X, M\2VVK6;MM5@L\6>)H\_,I_IZ'% 'V]15>SOK>^L;>\MY T,\:RQMGJK#(/Y& MB@"Q7AO[0GBKR;6R\,6\GS3?Z5= '^ '"*?J+[J_CA1^- 'MWPE\*_P#"+^![831[;Z^QNI^$/@P>%_"J7=U%MU/40)9LCF-/X4_+D^Y]J M\?\ NGW'Q-^*\VJZBA>V24WMPIY 4'$4C_D3^% '-:OJNK?%WQW% M:6(9+-25MD;[L,7\4K>Y_P !7T)X;\.V'A?18=,T^/$:#+N?O2-W9O7<1C_EG*/O#Z=Q[$5T5 M 'S3\5?#EQX%\;VWB'1\PV]S+]H@*CB*8'++]#UQZ$BO??"GB*V\5>&;+6+; M 6XCRZ9_U;CAE/T.:I^/O"\?B[P?>Z65'VC;YELQ_AE7E?SZ?0UX[\ _$\FG MZ]>^%KQBB7.Z6!&_@F3AU_$#_P =H ^AZ^;/C;X?F\,^-K7Q+IN8DO7$P=>- MEPF"?S&#^=?2=<;\4?#?_"3^ =1M43==0+]IM_7>G./Q&1^- &SX3U^'Q1X6 MT_68< 7,09U'\#CAE_ @ULUX-^SKXD+)J?AN9_NXN[<$]C@./SVG\37O- !1 M110 4444 %%%% !1110 4444 %%%% !7%?%RRFO_ (6Z[% "SK")<#J0C!C^ M@-=K39(TEC:.10R."K*PR"#U!H ^%_#6JKH7B;3-5:,R+:7,Q'8^QKYP^)'P3U31+R?4O#EN]]I3DN8(Q MNEM^^,=67T(Y]?6O,M*US6?#5\9],OKJPN%.&\MBN?9AT/T- 'W/AN+<".4>Y7[K?I7O'AKQ7HWB[31?:->I<1CATZ/&?1EZ@T ;( 4 #H.!2T4 M4 %%%% !1110 4444 ,E_P!2_P#NFO@BZ_X^IO\ KHW\Z^]Y?]2_^Z:^"+K_ M (^IO]]OYT ?;W@S_D1]!_[!\'_H KLCP3X 'C7X;ZY-9QC^V+&Z62V( MZR+L^:/\>WO]:U_VC?\ D>=._P"P>O\ Z&]=;^S7_P B[KG_ %]I_P"@4 >. M_#[QG=^ O%D=]AS:L?)O;?H63//']X=1^7>OLFQO;;4K&"]LYEFMIT$D?V9?'Q7I<.+.Z?%ZBCB.4]'^C=_?ZU8^ OQ#^R7(\(ZI-^XF M8M8.Q^XYZQ_0]1[Y]: /H*_&=.N@/^>+_P C7P2>IK[WO?\ CQN/^N3?RKX( M;[Q^M 'WGI?_ ""++_K@G_H(JW532_\ D$67_7!/_015N@ HHHH **** "BB MB@ KYG_:'\3R7WB>V\/1.?LUA&)95!^]*XSS]%Q^9KZ8KXK^)EPUS\2_$,C] M?MKH/HIVC]!0!W7P#\#0:WJ\_B+481):Z>X2W1AD/-C.3Z[1@_4CTKZ:KSKX M'6B6OPJTUD W3R2RN?4[R/Y 5Z+0 45RVH?$CP?I.H3V%]KUK!=0-LEB8-E3 MZ=*J_P#"V/ G_0RV?Y-_A0!K>+/".D^,]&;3-6A9HMP=)$.'C8=U/;TK@X_V M>O"4,B217NKI(A#*RSJ"I'0CY:Z;_A;'@3_H9;/\F_PH_P"%L>!/^AEL_P F M_P * .QC0QQ(A=G*J 6;JWN:=63H7B?1?$\$TVBZA%>QPL$D://RDC..16M0 M 4444 %%%% !1110 5QGQ9_Y)9X@_P"O8?\ H2UV=<9\6?\ DEGB#_KV'_H2 MT ?)GA+_ )'+0_\ K_@_]&+7W-7PSX2_Y'+0_P#K_@_]&+7W-0 5X%^TO_JO M#G^]/_[)7OM>!?M+_P"J\.?[T_\ [)0!B?LW_P#(Z:I_V#S_ .C%KZ8KYG_9 MO_Y'/5/^O _^C%KZ8H **** "BBB@ HHHH **** "O$_VD_^17T;_K];_P! M->V5XG^TG_R*^C?]?K?^@&@#SWX ?\E/B_Z\YOY"OJZOE'X ?\E/B_Z\YOY" MOJZ@ HHHH **** "BBB@ HHHH **** "O+/CQXH_L/P*=-ADVW6JOY(P>1$. M7/\ )?\ @5>IU\A?&;Q1_P )+\0;M89-UGI_^B0X/!*GYS^+9_ "@"Y\"O#? M]N?$&*]E3-MI:?:6STW]$'Y\_P# :/CIX:_L+X@2WD28MM43[2N.F_HX_/G_ M (%7L/P(\-_V)X 2_E3;&O[<\ 27T2;KG2W^T M+CJ8^CC\L'_@- &7^SUXH_M+PKQU\:?"OQ/_ M ,(KX_T^[D?;:SM]FN?38_&3]#@_A7V70 4444 %%%% !1110 4444 %?+?[ M0_\ R4:#_L'Q_P#H3U]25\M?M#_\E&@_[!\?_H3T =C^S3_R"/$'_7>'_P!! M:O=*\+_9I_Y!'B#_ *[P_P#H+5[I0 C*KJ58!E(P01P17PYXPTZ'2/&>M:?; MX$-O>2QQ@=E#' K[&\6^+=,\':%/J>HS*NU3Y,.[YYG[*H_SBOB^0WWB7Q$[ M)&TU_J-R2$49+.[=!^)H ]%TCQ?KUMHMC!"\OE16\:)CT"@"BO?='\!:1I^B M6%E-;K)+;VT<3O\ WF50"?THH J?%S73H'PVU2:-ML]R@M8B.N7X/_CNXUPO M[.>@B'2]4UZ1/FGD%K"3_=7EOS)'Y53_ &DM7(&B:,IX^>[D&?3Y5_\ 9J]3 M^&^CC0OAYHMD5"R?9EED_P!]_F/\Z .JKR/X_P#B,Z9X.@T:%\3:G+A\'_ED MF"WYG:/SKUROE[XM74OB_P",4.AV[%EA:*PC [,Q!<_^/?I0!ZG\#/#@T;P( MFHRIBYU1_/)/41CA!^63_P "KTZH+.TBL+&WLX%VPP1K&@]%48'\JGH R?$^ MO6_AGPU?ZQX_@*]#^%GAL>&? .GV[IMNK ME?M-QZ[W&'[;Q1XB@#YJ^$.O7/@_XA7'A MK4R8H[R0VTB-T2X4D*?QY'XBOI6OG#X]Z"^C>++'Q'9 QB\ W.O&V>/!!_$8 M_*O=?"6NIXE\)Z9K"8S=0*S@=GZ,/P(- &U7R_\ %.PF\"_%F'7+!=D<\BZA M%CIO!Q(OXG/_ 'U7U!7DO[0.AC4/!$.JHF9=-N Q('_+-_E;]=M 'J.G7T.I MZ;:W]LVZ"YB65#[,,C^=62,C!Z5YE\"=;.J_#F*TD?=+ILS6Q]=OWE_0X_"O M3: /E>+/PY^/@09CM!>[?;R)NGY;OTKZHKYT_:.TC[/KFD:U&N/M$+0.P_O( MA5S^O^ M"/#?B=&&KZ1;3N?^6P7;(/\ @8P?UKY\\ ?%SQ-)XYTJ'7M&KF6YMX5,DMG-S(JCDE6'WL>A&?K7F M'@WQ9?\ @WQ';:K8R, C 3Q9^6://*G^GH:^U=3O+;3M+NKV\=4MH(FDE9N@ M4#)KX.F=9)Y'1=J,Q*KZ#- 'WK:7,5[9P74)W13QK(A]5(R/YU-6-X2MY+3P M=HMO-GS([&%6SZA!6S0 4444 %%%% !1110 R7_4O_NFO@BZ_P"/J;_KHW\Z M^]Y?]2_^Z:^"+K_CZF_ZZ-_.@#[>\&?\B/H/_8/@_P#0!6Y6'X,_Y$?0?^P? M!_Z *W* "BBB@ HHHH **** "BBB@#YC_:-_Y'G3O^P>O_H;UUG[-9_XD&NC MM]JC_P#0#7)_M&_\CSIW_8/7_P!#>NK_ &:O^0#KO_7U'_Z": /:-1T^UU;3 MKC3[V%9K6XC,.O"%[X!\6R6):3R@WG65R."Z9^4Y_O#H?<5]J5 MQ?Q-\"P^.O"\EJH5=1M\RVU &=\-/'T?CCP5-]H=1JUG$8 M[M/[W!Q(!Z''YYKY&;[Q^M=%X9\0ZGX#\4_:DC=)82UO=VS\;UZ,C>_\B!7/ M,06)'0GB@#[RTO\ Y!%E_P!<$_\ 015NJFE_\@BR_P"N"?\ H(JW0 4444 % M%%% !1110 5\O$_V@O!K5\:?#/QW-X#\3K=L&DT^X BNXEZE<\,/<=?S'>OK[2=7L-&[#1K;F.TA$>[^\W5F_$DG\:U: "BBB@ HHHH **** "N,^+/_ "2SQ!_U M[C_T):[.N:^(.G2:K\/M>LH5W2R6I4@_P!*^Z=(U2UUO2+34[*026UU$)$8'L>W MU'2@"[7@7[2_^J\.?[T__LE>^U\R_M$:_;ZCXJL=(MY YTZ%O.(/ D<@[?J M!^= #OV;_P#D<]4_[!Y_]&+7TQ7SM^S7I\C:IKNI%?W20QVX;U);<1_XZ/SK MZ)H **** "BBB@ HHHH **** "O$_P!I/_D5]&_Z_6_] ->V5XG^TG_R*^C? M]?K?^@&@#SWX ?\ )3XO^O.;^0KZNKY1^ '_ "4^+_KSF_D*^KJ "BBB@ HH MHH **** "BBB@ HHHH Y;XB>)E\)>!]2U0,!<"/RK<>LK<+^77\*^-+!(+K5 M;=+ZX\FWDF43S$$[5)^9N.3QFO8OVB?%'VS7++PW!)F*R7S[@ ]96'RC\%_] M"KA/!/PTUSQY#=SZ6UM'#:LJ.]PY4%CS@8![?S% 'T1:_&'X=V5I#:P:T$AA M18XU%M+PH& /N^@I;GXQ?#N[M9K:?6@\,R&-U-M+@J1@C[OI7D/_ SKXO\ M^?S2O^_S_P#Q%'_#.WB__G\TK_O\_P#\10!Y;J<5K;ZI=16-Q]HM$E80S $; MTS\IP>>F*^P/A5XG_P"$J\ :?=R/NN[=?LUSZ[TXR?J,'\:^9_&WPRUWP';6 MESJC6LL-RY17MW+!6 S@Y ZCI]#78?L]^*/[,\5W&@SR8M]23,0)X$R D?FN M?R% 'TY1110 4444 %%%% !1110 5\M_M#_\E%@_[!\?_H3U]25\M_M#_P#) M1H/^P?'_ .A/0!V'[-/_ ""/$'_7>'_T%JY_XPW?C3P?XG9K;Q'JHTB_S);8 MN& C/\4?'IGCV(KH/V:?^01X@_Z[P_\ H+5Z=X]\(6_C7PG=:5+M6?'F6TI' M^KE'W3]#T/L30!\I^&/#.O?$O6Y+:/4XY;N-/,9[^X8MMS@D9R3CVKZ)^'7P M?TOP1*-1N9O[0U?;@3%<)#GKL'K[GGZ5\R:7J&J^"/%D=U$K6^HZ=.5>-N.0 M<,A]B,BOL[PSXALO%/AZSUBP;,-PF2N>4;HRGW!R* -:BBB@#Y;^++GQ'\;X MM*4EE1[:R ]-Q!/_ *&:^HD18XUC0850 .P%?+VB#^V_P!I9Y/O*NJS2?A& M&Q_Z"*^HZ &2R+#$\KG"(I9CZ 5\O_"6)O%/QIEU>8%Q&UQ?,3V).%_5A^5? M07CN_.F> M>NP<-'8R[3[E2!^IKQW]FJPS<:_J!'W4B@4_4LQ_D* /H.BBJF MJ7@T[2+V];I;P/*?^ J3_2@#YDU;_BOOV@#:D^9;?;E@XZ>5#][\]K?G7U, M , 8 KYF_9\LFU'Q]J&J3?,UO:L^?]N1@/Y;J^F: "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@#@/C-H@UGX:Z@RKNFLL7_\ '2UZ5(<>?;2Q,/]J-@?Y!J /IRL;Q;I:ZWX1U?36&?M%K( MBC_:VG;^N*V:* /G/]G'5&A\0:SI+M@3VZSJI_O(VT_HWZ5]&5\M_#[_ (I[ M]H.2P^ZIN[JUQ['<1_(5]24 >5?M ::+SXRNXY,^BME3_Z$*E^ 6H_ M;?AI';LV6LKJ6'Z D./_ $*NC^)]G]N^&?B"'&2+1I!]5PW]*\U_9JO-VGZ_ M9$_T6U M\1:#>Z1> FWNXC&Q'5<]"/<'!_"M&B@#X>\6^$M4\&ZW+INIPLI4DQ3 ?),G M9E/].U=KX9^//B?0-/CL;J*WU2&)0L;W&1(H'0%AU_$9]Z^G-8T/2_$%D;/5 MK""\MSSLF3.#Z@]0?<5YW>?L_>"KF4O"-0M03G9%<94?]] G]: /#_&OQ9\1 M^-K?['=/%::?G)M;8$!SVW$G)^G3VJW\)_AU=^,?$$%Y>5A@2D' M(C7USW]!^%>W:5\"?!&FS++):7-\R\@74Q*_]\J #^->C6UK;V5M';6L$<$$ M8VI'&H55'H * )0 !@# %%%% !1110 4444 %%%% #)?]2_^Z:^"+K_CZF_W MV_G7WR0&!!Z'BN#;X,> G8L="7).3_I$G_Q5 '0^#/\ D1]!_P"P?!_Z *W* M@LK.#3[&"RM4\NW@C6*-,YVJHP!S[5/0 4444 %%%% !1110 4444 ?,?[1W M_(\Z=_V#U_\ 0WKJ_P!FHC^PM>'?[3'_ .@FO2_$7P_\,^++Z.]UK31=7$!?'O MX>;E/C#2X?F&%U"-!U'02_T/X'UKY]K[[G@BNK>2WGC62&52CHPR&4C!!KA3 M\%_ )_Y@*_\ @1+_ /%4 =GI?_((LO\ K@G_ *"*MTR*)(84BC&$10JCT X% M/H **** "BBB@ HHHH *;)&DT3Q2(KQN"K*PR&!Z@BG44 ?-'Q,^"-[I5Q-J M_A>W>ZTYB7DLT&9(/7:/XE_4>_6O,_#_ (KU_P (WC2:/J$]F^?WD75&(_O( M>#^5?<=?!LDFZ.; M5(A_=6=2/U6M#3?@5X&T^19)+*XO6':YG)'Y+@4 ?,>B>'M=\8:J8--M+B^N MI&S)(IZFNYT_3; M'2K1;73[."UMUZ1PQA%_(5:H **** "BBB@ HHHH **** "@@$8(R#110!\H M_%SX7W?A35I]6TV!I-#N7+@H,_9F/5&]!Z'\*Y[P=\2_$G@E6ATRZ22S9MS6 MMPN^//A%>?:S\$O!&L3--_9TEE(W)-G* M8QG_ '>5'X"@#QO5OV@O%VH6C06L5CIY88,L$99Q]"Q('Y5Y[H^C:QXNUU;. MPAFO;ZX@]2:^DK;]GOP7!*'E?4KA1_ ]P #_WRH/ZUZ%H7AO1 MO#5I]ET;3H+.(_>\M>6]V;J?QH S/ '@VW\#^%8-)B<2SD^;$]6&IZ1,L-V$:,,R!QM/ M7@\5V'_"]/'W_04@_P# 2/\ PKWK_A2_@'_H K_X$2__ !5'_"E_ /\ T 5_ M\")?_BJ /!?^%Z>/O^@I#_X"1_X5]1^&;V?4O"NDWUTP>XN+.*61@, LR@DX M[I7;;;>UA:5S[*,UH% 'Q!K>K7&O:Y>ZK=',]W,TK>V3P/H!Q^%?7GPK\,_\ M"+?#_3K.1-MU,OVFX]=[\X/T&!^%5XO@WX#AFCE30DWHP9\"75U+<2Z$ADEA_#TKZ>OK&VU*QGL;R%9K:=#'+&XX92,$5 MQ/\ PI?P#_T A_X$2_\ Q5 '?45'#"EO!'"F[9&H1=S$G &.2>310!\P?!H_ M;OC7/='D[;J;\SC_ -FKZCKY;^ 'S?$^X-O\*=: M(/,BQQ_G(M/9PW^-?4=?+MQ\O[3@V_P#083]0,T ?45%%% 'RYJW_ M !+OVF58< ZM"W_?87/\Z^HZ^7/'7R_M'1$&M8V_)L?UKZ"U89T:^!_Y]Y/\ T$U\Z_LW?\C? MJW_7A_[46@#Z6HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@#Y<^!X^R_&">W/!\FXCQ[@@_TKZC MKY<\&G^QOVCI;<_*&U&ZA_!M^/Z5]1T >>_&V$S?"C5L#[AB?\I%KG_V@SRMQ$^/JI']*]RKYN_9POQ!XGU?3G.#/:K(%/JC8/Z-7 MTC0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?+ MNGG^T?VFBR<@:O(?P0'_ .)KZ?EE2&%Y7.$12S'T YKYA^#$;:W\9+C5"I8( MES=$^A<[1_Z'0!]0T444 ?+GB3_3_P!I:-!SC5+9/^^0G^%?4=?+GAD_V]^T MBURO*#4KB;/L@;'\A7U'0!G:_((?#FIRGHEI*WY(:^?OV;(\^)]:D_NV2K^; MC_"O;?B'=_8?AWX@N,X(L95'U9=H_G7DW[--H0/$-X1Q^YB!_P"^B?Z4 >_4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110!\M>.L^&?VA$O_ +J&]MKK/^RVW=_[-7U+7SI^T?I+ M0ZYHVKHN!/ UNS#^\AW#]&_2OQAOU!H U+VV M6]L+BT?[D\31M]&!']:^:/@1=/HOQ/N](F.UIX);<@_WXVS_ $:OIZOEGQ@& M\"_'O^TE&V WD=Z,<9CD^_\ S>@#ZFHI%97174@JPR".XI: /EG0C_P@O[03 M6SG9;_;W@YX'ES?=/_CR_E7U-7SI^T)H+V7B/3/$5N"HNH_)D<=I4Y4_E_Z# M7MO@O7T\3^$--U92"\\(\T?W9!PP_,&@#>HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH Y'XG:T-"^'6LW8;;*\!@B]V?Y1_,G\*\U M_9OTG?# M/P\?#/P_TJPD7;<-'Y\__71_F/Y9 _"@#K:I:Q?II6B7VH.0%MK=Y23_ +*D M_P!*NUYO\<=:&D_#:ZMU8";4)%M5'?!.6_0'\Z /+_V>[%]0\>:CJTN3]GM6 M)/\ MR,/Z!J^F*\@_9YT8V7@N[U1UP^H7)VG'5$&T?J6KU^@#S;XZZA]A^%] MY$&PUW-% /?YMQ_1369^SQI_V;P!<7A'-W>NP/JJ@*/U!KGOVDM6&W1-'4\Y M>ZD&?^ K_P"S5ZG\-M).B?#K0[)EVR"U61Q_M/\ .?\ T*@#JJ*** "BBB@ MHHHH **** "BBB@ HHHH **** "BL'Q9XPT;P9I1O]7N=BGB*).9)6]%'?Z] M!7SWXE_:!\3:G*\>BQPZ5:]%(422D>Y/ _ 4 ?45%?&O_"=?$6X'VA=9UMDZ M[D+[?T&*U]#^.GC31YE%Y3:9I.HK!:+!$ZH8$;DCG MD@F@#Z"HKF_ .JWFM^ ]'U/4)1+=W-N'E<*%W')[#BNDH ***\R^(/QETCP; M-)IUE&-2U=>&B5L1PG_;;U]ASZXH ]-HKY"U3XR^/-;N"(=3:T5C\L-C$%Q^ M/+'\ZI_\+ ^(FFD32ZWK$8SG,^XJ?P88H ^R:*^;_"?[0^IVL\=OXGM([RV) M -S;J$E7W*_=;\,5]!:/K.GZ_I<.I:7=1W-I,,K(A_,$=B/0T 7J*** "BOG MKXL?$[Q9X8\?W6EZ3J2P6D<43*A@1L$J">2">M2?"7XN:[KGC--'\17R3PW< M3+;GRE3;*.0/E Z@$?7% 'T#1110 45B>+O$$7A?PGJ6LRD?Z-"6C4_Q.>%' MXL17R]_PN_Q__P!!E/\ P%B_^)H ^O**Y#X8:YJ'B/X?:;JFJ3":\F\S>X0+ MG#L!P..@%=?0 45B>,=0N=)\&:SJ%E(([JVLY)8G*@[6"D@X/6O"_AG\5/&' MB+X@Z7I>IZFLUG.7\Q! BYPC$<@9Z@4 ?1]%%% !103@9/2O&O'GQZL-#N)= M-\.0QZC>1DJ]RY/D(?08Y<_3 ]S0![+17QY=_%;X@:W#^#B@#['HKPGP1^T'%>3Q6/BRWCMFZ1R)-$DL3J\;@,K*A!H =1110 45XI\3?C@V@:A-H? MAJ.*:]A.VXNY!N2)NZJ.Y']>2CQY\2=4W7D.K:U+&"27ME81C_OD8H ^ MQ:*^7/"'QY\1:1>1P^(&_M2P+8D9E"S(/4$8S]#^8KZ:T[4+75M.M]0LIEFM M;B,212+T930!9HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@#S7XYZ'_ &O\-[BY1-TVG2K= M+Z[1\K?HV?PK+_9[UP7W@RYTEVS+IUP=HS_RS?YA^NZO5K^SAU'3[FRN%W0W M$31./56&#_.OF7X77LW@3XNS:'>MLCFD?3Y<]-P.8V_$X_[ZH ^HJ\-_:+\/ M>=IVF>(8DR8'-K.1_=;E3^!!'_ J]RK(\4Z%#XF\,:AH\^-MU"45C_"W56_ M@&@#GOA+XB_X2/X>Z?+(^ZYM%^R3^NY. ?Q7::[BOFOX)Z]-X8\<7?AO4LQ+ M>L861N-EPA('YC(_*OI2@#E/B-X7'B[P3?Z:B@W2KYUL?25>0/QY'XUY3\ ? M%)L]0N_"UXQ03DS6ROQMD'#I]2!G\#7T#7S=\6O#-SX.\;0>)])S#!=S"='0 M<17 Y(^C=?SH ^D:*P/!OBBV\7^&K;5;?"NPV3Q9YCD'WE_J/8BM^@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "J]]>V^FV%Q?74@CM[>-I)' M/90,FK%>'_'3QJ!$OA2PDRS8DOBI[=5C_'@G\* .,\+V=Q\4?C VHW<9-HLW MVN=3R$B0XC3\<*/SKZCK@/A)X,/A/PFLMU'MU/4,37&>J#'RI^ //N37?T % M?-GQZUN36_&ECX=LR9/L2A=B\YGE(X_ ;?SKZ!U_6;;P]H-[JUVP$-K$9"/[ MQ[ >Y.!^-?._PCT>Y\9_$VX\1:B#(EH[7DK'H9F)V+^')_X"* /H3PQHL?AW MPQIND18Q:6ZQDCNV/F/XG)K6HK#\8Z_'X8\(ZEJ[D!K>$F,'^*0\*/S(H ^= M/&CMX^^.JZ;"=\ NH[%<<@(G^L/Y[S7U,B+&BH@ 51@ =A7SG^S[H,FH^*-1 M\1W(+BT0QHY[RROTZ5Y7^SKH\-[XTO=1E4,;"U_=Y[.YQG\@WYU].T M (JJJA5 "CH .*Y'QA\-?#GC*TD6\LHX+PC]W>0*%D4^_P#>'L:Z[//"?BV<3,C^C CU'4'W!KZG\)ZM?:UX: ML[W4]/FL+]DVW%O,A0JXX) /8]1]:V=R_P!X?G0"#T(H 6LSQ'_R*^K?]>4W M_H!K3K,\1_\ (KZM_P!>4W_H!H ^/?AM&DOQ)\/1R(KHUZ@*L,@C/I7V1_8^ MF?\ 0.M/^_"_X5\4^#]8M_#_ (PTG5[I)'@M+A976, L0/3-?0?_ T9X3_Z M!^J_]^T_^*H ]3_L?3/^@=9_]^%_PJXJJBA54*H& , "O(/^&C/"?\ T#]5 M_P"_:?\ Q5>M6MPEW9P7,8(2:-9%!Z@$9H FKPO]I;_D#^'_ /KXE_\ 05KW M2O"_VEO^0/X?_P"OB7_T%: /!$TJ_31EUR-&%HMS]G\Y#RDH4,,^G'0^QKZL M^$?Q 7QMX:$-W(/[8L0$N03S(/X9!]>_O]17"_ W0[+Q-\-O$>CZC&'MKB[V MGU4[%PP]P0"*\TB?6_A!\2/F!,MH^&'1+J!OZ$?D1[4 ?9%?*'Q^_P"2H3?] M>D/\C7T_H>M67B'1;75M/E$EKH/H0<@_2OF#X_?\ )4)O^O2'^1H M]_\ A7_R2[P]_P!>@_F:["N/^%?_ "2[P]_UZ#^9KL* /._C#XZ?P7X4VV4F MW5+\F*W/>,8^9_P!&/ ;[XA^(9(VE>*RA(DO+H\GD]!GJQY_4UT? M[0FI277Q$2S+?N[.T15'NV6)_4?E7L/P1T6+2?AEI\RJ/.ORUS*V.3DX7_QT M"@#J?#O@[0/"MFEOI&FP08',NW,CGU9CR:V9H8KB)HIHDDC;@HZ@@_@:?10! MXE\4O@K87FGW&M>%[5;:^A4R2V<0Q'.HY.T?PM[#@_6O,OA%X]G\'>*(K6YE M;^R+Z01W",>(V/ D'H1W]OH*^NJ^,_BMHL6@_$G6+2! D#RB>-1T =2DU?P#H5]*\^K 8)_,5T= 'R7\>/^2JWW_7"'_T 5A^ M(])N/!/B#1M1LBR+/:6VHVK^C%02/P8'\*W/CQ_R56^_ZX0_^@"N[^)'AG^U MO@?X(?#UAJ]L?W5W"LH']TD;'Y@/HW/_ *O;I98X(7FE8)' M&I9F/0
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end EX-101.SCH 4 omic-20211109.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 omic-20211109_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Interactive Data Current Entity Current Reporting Status Entity Current Reporting Status Current Fiscal Year End Date Current Fiscal Year End Date Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Transition Report Document Transition Report Document Quarterly Report Document Quarterly Report Document Type Document Type Entity Registrant Name Entity Registrant Name Cover [Abstract] Entity Central Index Key Entity Central Index Key Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Security Exchange Name Security Exchange Name Title of 12(b) Security Title of 12(b) Security Local Phone Number Local Phone Number City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Address, State or Province Entity Address, State or Province Entity Address, City or Town Entity Address, City or Town Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, Address Line One Entity Address, Address Line One Entity Tax Identification Number Entity Tax Identification Number Entity File Number Entity File Number Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Year Focus Document Fiscal Year Focus Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Shell Company Entity Shell Company Trading Symbol Trading Symbol Entity Ex Transition Period Entity Ex Transition Period Entity Emerging Growth Company Entity Emerging Growth Company Entity Small Business Entity Small Business Entity Filer Category Entity Filer Category Entity Interactive Data Current Entity Information, Former Legal or Registered Name Written Communications Soliciting Material Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer EX-101.PRE 6 omic-20211109_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 7 omic-20211109_htm.xml IDEA: XBRL DOCUMENT 0001850906 2021-11-09 2021-11-09 0001850906 false 8-K 2021-11-09 Singular Genomics Systems, Inc. DE 001-40443 81-2948451 10931 N. Torrey Pines Road Suite #100 La Jolla CA 92037 858 333-7830 N/A false false false false Common Stock, par value $0.0001 per share OMIC NASDAQ true false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document and Entity Information
Nov. 09, 2021
Cover [Abstract]  
Entity Registrant Name Singular Genomics Systems, Inc.
Entity Central Index Key 0001850906
Document Type 8-K
Entity Information, Former Legal or Registered Name N/A
Document Period End Date Nov. 09, 2021
Amendment Flag false
Entity Emerging Growth Company true
Entity Ex Transition Period false
Trading Symbol OMIC
Entity File Number 001-40443
Entity Tax Identification Number 81-2948451
Entity Address, Address Line One 10931 N. Torrey Pines Road
Entity Address, Address Line Two Suite #100
Entity Address, City or Town La Jolla
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92037
City Area Code 858
Local Phone Number 333-7830
Written Communications false
Soliciting Material false
Pre-commencement Issuer Tender Offer false
Pre-commencement Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Security Exchange Name NASDAQ
Entity Incorporation, State or Country Code DE
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://singulargenomics.com/20211109/taxonomy/role/Role_DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports omic-20211109.htm omic-20211109.xsd omic-20211109_lab.xml omic-20211109_pre.xml omic-ex99_1.htm http://xbrl.sec.gov/dei/2021 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "omic-20211109.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "omic-20211109.htm" ] }, "labelLink": { "local": [ "omic-20211109_lab.xml" ] }, "presentationLink": { "local": [ "omic-20211109_pre.xml" ] }, "schema": { "local": [ "omic-20211109.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" ] } }, "elementCount": 37, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "omic", "nsuri": "http://singulargenomics.com/20211109", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "omic-20211109.htm", "contextRef": "C_981ad0a6-cc67-44c3-89a3-b64d744d80f9", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://singulargenomics.com/20211109/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "omic-20211109.htm", "contextRef": "C_981ad0a6-cc67-44c3-89a3-b64d744d80f9", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://singulargenomics.com/20211109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://singulargenomics.com/20211109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://singulargenomics.com/20211109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://singulargenomics.com/20211109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://singulargenomics.com/20211109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://singulargenomics.com/20211109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://singulargenomics.com/20211109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://singulargenomics.com/20211109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://singulargenomics.com/20211109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://singulargenomics.com/20211109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://singulargenomics.com/20211109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://singulargenomics.com/20211109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://singulargenomics.com/20211109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://singulargenomics.com/20211109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://singulargenomics.com/20211109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://singulargenomics.com/20211109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://singulargenomics.com/20211109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://singulargenomics.com/20211109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://singulargenomics.com/20211109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://singulargenomics.com/20211109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://singulargenomics.com/20211109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://singulargenomics.com/20211109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationFormerLegalOrRegisteredName": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Former Legal or Registered Name of an entity", "label": "Entity Information, Former Legal or Registered Name" } } }, "localname": "EntityInformationFormerLegalOrRegisteredName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://singulargenomics.com/20211109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://singulargenomics.com/20211109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://singulargenomics.com/20211109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://singulargenomics.com/20211109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://singulargenomics.com/20211109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://singulargenomics.com/20211109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://singulargenomics.com/20211109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://singulargenomics.com/20211109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://singulargenomics.com/20211109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://singulargenomics.com/20211109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://singulargenomics.com/20211109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://singulargenomics.com/20211109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://singulargenomics.com/20211109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://singulargenomics.com/20211109/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r10": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r6": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r7": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r8": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r9": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0000950170-21-003731-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-21-003731-xbrl.zip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end